Ticagrelor contraindications: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{JH}} | {{CMG}}; {{AE}} {{JH}} | ||
== | ==Contraindications== | ||
====History of Intracranial Hemorrhage==== | ====History of Intracranial Hemorrhage==== | ||
BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage]] (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)]. | BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage]] (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)]. | ||
====Active Bleeding==== | ====Active Bleeding==== | ||
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or [[intracranial hemorrhage]] [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. | BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or [[intracranial hemorrhage]] [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. | ||
====Severe Hepatic Impairment==== | ====Severe Hepatic Impairment==== | ||
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)]. | BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)]. | ||
====Hypersensitivity==== | ====Hypersensitivity==== | ||
BRILINTA is contraindicated in patients with hypersensitivity (e.g. [[angioedema]]) to ticagrelor or any component of the product [see Adverse Reactions (6.2)]. | |||
BRILINTA is contraindicated in patients with hypersensitivity (e.g. [[angioedema]]) to ticagrelor or any component of the product [see Adverse Reactions (6.2)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist | {{Reflist}} | ||
[[Category:ADP receptor inhibitors]] | [[Category:ADP receptor inhibitors]] | ||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 22:51, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Contraindications
History of Intracranial Hemorrhage
BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)].
Active Bleeding
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Severe Hepatic Impairment
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)].
Hypersensitivity
BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions (6.2)].[1]